252 related articles for article (PubMed ID: 20806817)
1. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
2. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
3. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
4. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
5. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
6. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
7. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
8. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
9. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
10. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
12. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
13. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
15. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.
Jalkanen SE; Vakkila J; Kreutzman A; Nieminen JK; Porkka K; Mustjoki S
Exp Hematol; 2011 Jan; 39(1):102-113.e1. PubMed ID: 20869423
[TBL] [Abstract][Full Text] [Related]
16. Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.
Filippi I; Naldini A; Carraro F
Curr Med Chem; 2011; 18(19):2885-92. PubMed ID: 21651491
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Krupkova L; Mojzikova R; Novotny J; Gazdova J; Divoka M; Skoumalova I; Rohon P; Jarosova M; Indrak K; Faber E; Divoky V
Int J Lab Hematol; 2015 Feb; 37(1):e11-5. PubMed ID: 24845482
[No Abstract] [Full Text] [Related]
18. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
19. [Protein tyrosine kinase inhibitors in cancer therapy].
Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
[TBL] [Abstract][Full Text] [Related]
20. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
